ZNF93: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: ZNF93

NCBI ID: G81931

ZNF93

ZNF93: A Potential Drug Target Or Biomarker for Various Diseases

ZNF93 (HPF34) is a gene that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. ZNF93 is a member of the Zinc Finger Nucleotide (ZNF) family, which is known for its role in regulating gene expression and cell growth.

The ZNF93 gene is located on chromosome 6p21.2 and has been shown to encode for a protein that is involved in various cellular processes, including cell adhesion, migration, and survival. ZNF93 has also been shown to play a role in regulating the expression of other genes, including APCAM9, which is associated with cancer risk.

One of the key features of ZNF93 is its potential to interact with the protein known as p53, which is a well-known tumor suppressor protein. p53 is often activated in response to DNA damage or other stressors, and it plays a critical role in regulating cell growth and apoptosis. By interacting with p53, ZNF93 has been shown to regulate its activity and influence the expression of genes involved in cell growth, differentiation, and survival.

In addition to its potential role in regulating p53 activity, ZNF93 has also been shown to interact with several other proteins, including TGF-β1, NF-kappa-B, and SMAD. These proteins are involved in various cellular processes, including cell signaling, gene expression, and cellular adhesion, and are known to play important roles in the development and progression of many diseases.

Given its potential role in regulating the activity of p53 and other proteins, ZNF93 has been considered as a drug target or biomarker for various diseases. For example, ZNF93 has been shown to be involved in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. By targeting ZNF93 with drugs that can modulate its activity, researchers may be able to develop new treatments for these devastating conditions.

In addition to its potential as a drug target or biomarker, ZNF93 has also been shown to be involved in the development of certain types of cancer. For example, ZNF93 has been shown to be involved in the development of cervical cancer, and studies have suggested that targeting ZNF93 with drugs may be an effective way to treat this aggressive form of cancer.

Another promising aspect of ZNF93 is its potential to serve as a biomarker for certain types of cancer. By analyzing the expression of ZNF93 in cancer cells, researchers may be able to identify new biomarkers for cancer diagnosis and treatment. For example, ZNF93 has been shown to be involved in the regulation of the cell cycle, and certain types of cancer cells have been shown to have altered levels of ZNF93 expression. By targeting these cells with drugs that can modulate ZNF93 activity, researchers may be able to develop new treatments for cancer.

In conclusion, ZNF93 is a gene that has been identified as a potential drug target or biomarker for various diseases. Its ability to interact with the protein known as p53 and other proteins involved in cellular processes makes it an attractive target for drug development. Furthermore, its potential involvement in the development of neurodegenerative diseases, cancer, and other conditions makes it an important area of research for scientists and clinicians alike. As research continues to advance, it is likely that new treatments and therapies will be discovered that can help to alleviate the suffering caused by these diseases.

Protein Name: Zinc Finger Protein 93

Functions: Transcription factor specifically required to repress long interspersed nuclear element 1 (L1) retrotransposons: recognizes and binds L1 sequences and repress their expression by recruiting a repressive complex containing TRIM28/KAP1 (PubMed:25274305). Not able to repress expression of all subtypes of L1 elements. Binds to the 5' end of L1PA4, L1PA5 and L1PA6 subtypes, and some L1PA3 subtypes. Does not bind to L1PA7 or older subtypes nor at the most recently evolved L1PA2 and L1Hs. 50% of L1PA3 elements have lost the ZNF93-binding site, explaining why ZNF93 is not able to repress their expression (PubMed:25274305)

The "ZNF93 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF93 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets